Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort.

Authors

Zhen Cai, Zhongjun Xia, Aili He, Yujun Dong, Yafei Wang, Aijun Liao, Yang Song, Hongye Chen, Athena Zuppa, Katherine Chastain, Latisha Watkins, Xinchao Luo, Lin Huang, Hongmei Xu, Longen Zhou, Wannan Chen, Angeline Zhu, Xiaohong Wang, Juan Du, Ting Niu, Weijun Fu

Published in

EJHaem. Volume 7. Issue 4. Pages e70340. Epub Jul 30, 2026.

Abstract

With an additional year of follow-up compared with the previous report, this study presents the 27.2-month efficacy and safety outcomes of the MajesTEC-1 China cohort.
A total of 26 participants with triple‑class exposed relapsed/refractory multiple myeloma (TCE-RRMM) received subcutaneous teclistamab 1.5 mg/kg weekly, with potential transition to every 2 weeks in sustained responders.
Overall response rate (ORR) was 76.9%, with all responders achieving a very good partial response or better (≥ VGPR), and 75% achieving a complete response or better (≥ CR). Median progression‑free survival (PFS) was 25.1 months, while median duration of response (DOR) and overall survival (OS) were not reached. Among patients achieving ≥ CR, estimated 30‑month DOR, PFS, and OS rates were favorable at 80.0%, 80.0%, and 93.3%, respectively. Patients with poor prognostic features achieved ORRs comparable to overall population, and their DOR was generally consistent. Quality-of-life assessments showed improvements from baseline in global health status, physical functioning, fatigue, and pain. Safety profile was consistent with previous publication. Incidence of new-onset Grade ≥ 3 infections decreased over time, which was consistent with the timing of transition to biweekly dosing and may be related to immunoglobulin use.
These findings support teclistamab as a standard-of-care for patients with TCE-RRMM in China.
ClinicalTrials.gov identifier: NCT03145181/NCT04557098.

PMID:
42534634
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.